In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a novel type of immunotherapy.
With NCI Director Anthony Letai in Milan supporting his daughter, Julie, at the 2026 Winter Olympics, Douglas R. Lowy, principal deputy director of NCI, took on the job of delivering detailed remarks and fielding questions at the inaugural meeting of the NCAB’s ad hoc working group on Extramural Research Concepts and Programs.
